I-Glucosamine Hydrochloride

-Delile

• Ubufakazi obanele bokukala ukusebenza kwe ...
• Ukuqapha okukhethekile nezixwayiso:

I-Glucosamine ushukela we-amino okhiqizwa ngokwemvelo kubantu. Futhi itholakala kumagobolondo asolwandle, noma ingenziwa elebhu. I-Glucosamine hydrochloride ingenye yezinhlobo eziningana ze-glucosamine.

Kubalulekile ukufunda amalebula emikhiqizo ye-glucosamine ngokucophelela ngoba izinhlobo ezahlukahlukene ze-glucosamine zithengiswa njengezithasiselo. Le mikhiqizo ingaqukatha i-glucosamine sulfate, i-glucosamine hydrochloride, noma i-N-acetyl glucosamine. Lawa makhemikhali ahlukene anokufana okuthile. Kepha kungenzeka bangabi nemiphumela efanayo lapho bethathwa njengesengezo sokudla. Iningi locwaningo lwesayensi nge-glucosamine lwenziwe kusetshenziswa i-glucosamine sulfate. Bona uhlu oluhlukile lwe-glucosamine sulfate. Imininingwane ekuleli khasi imayelana ne-glucosamine hydrochloride.

Izithako zokudla eziqukethe i-glucosamine zivame ukuqukethe izithako ezingeziwe. Lezi zithako ezingeziwe zivame ukuba yi-chondroitin sulfate, i-MSM, noma uqwanga lukashaka. Abanye abantu bacabanga ukuthi le nhlanganisela isebenza kangcono kunokuthatha nje i-glucosamine iyodwa. Kuze kube manje, abacwaningi abatholanga bufakazi bokuthi ukuhlanganisa izithako ezingeziwe ne-glucosamine kunezela noma iyiphi inzuzo.

Imikhiqizo equkethe i-glucosamine ne-glucosamine kanye ne-chondroitin yehluka kakhulu. Amanye aqukethe lokho okushiwo ilebula. Umehluko ungasuka ku-25% kuye ku-115%. Eminye imikhiqizo e-US ebhalwe ukuthi i-glucosamine sulfate empeleni i-glucosamine hydrochloride ene-sulfate eyengeziwe. Lo mkhiqizo ungahle ube nemiphumela ehlukile kunaleyo equkethe i-glucosamine sulfate.

I-Glucosamine hydrochloride isetshenziselwa i-osteoarthritis, i-rheumatoid arthritis, i-glaucoma, isifo somhlathi esibizwa nge-temporomandibular disorder (TMD), ubuhlungu bamalunga, nezinye izimo eziningi, kepha abukho ubufakazi obuhle besayensi bokuxhasa lokhu kusetshenziswa.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze IGLUCOSAMINE HYDROCHLORIDE zimi kanje:

Ubufakazi obanele bokukala ukusebenza kwe ...

• Isifo senhliziyo. Abantu abathatha i-glucosamine bangaba nengozi ephansi yokuhlaselwa yisifo senhliziyo. Kepha akucaci ukuthi imuphi umthamo noma uhlobo lwe-glucosamine olungasebenza kahle kakhulu. Ezinye izinhlobo ze-glucosamine zifaka phakathi i-glucosamine sulfate ne-N-acetyl glucosamine. Akucaci futhi ukuthi le ngozi engezansi ivela ku-glucosamine noma ekulandeleni imikhuba yokuphila enempilo.
• Ukucindezeleka. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-glucosamine hydrochloride amasonto ama-4 kungahle kuthuthukise izimpawu zokudangala kwabanye abantu abanokudangala.
• Isifo sikashukela. Abantu abathatha i-glucosamine bangaba nengozi ephansi yokuba nesifo sikashukela. Kepha akucaci ukuthi imuphi umthamo noma uhlobo lwe-glucosamine olungasebenza kahle kakhulu. Ezinye izinhlobo ze-glucosamine zifaka phakathi i-glucosamine sulfate ne-N-acetyl glucosamine. Akucaci futhi ukuthi le ngozi engezansi ivela ku-glucosamine noma ekulandeleni imikhuba yokuphila enempilo.
• Izinga eliphakeme le-cholesterol noma amanye amafutha (lipids) egazini (hyperlipidemia). Ucwaningo lwakuqala luphakamisa ukuthi i-glucosamine hydrochloride ayithinti amazinga e-cholesterol noma we-triglyceride kubantu abane-cholesterol ephezulu.
• Isifo esithinta amathambo namalunga, imvamisa kubantu abanesifo selenium (isifo seKashin-Beck). Ubufakazi bokuqala bukhombisa ukuthi ukuthatha i-glucosamine hydrochloride kanye ne-chondroitin sulphate kunciphisa ubuhlungu futhi kuthuthukise ukusebenza komzimba kubantu abadala abanesifo samathambo nesihlanganisi esibizwa ngesifo iKashin-Beck. Imiphumela ye-glucosamine sulfate ezimpawu zesifo seKashin-Beck iyaxubana lapho isithasiselo sithathwa njenge-ejenti eyodwa.
• Ubuhlungu emadolweni. Kunobunye ubufakazi bakuqala bokuthi i-glucosamine hydrochloride ingadambisa izinhlungu kwabanye abantu abanobuhlungu obuqhutshwa njalo emadolweni. Kepha olunye ucwaningo lukhombisa ukuthi ukuthatha i-glucosamine hydrochloride kanye nezinye izithako akubutholi ubuhlungu noma kuthuthukise ikhono lokuhamba kubantu abanezinhlungu zamadolo.
• I-osteoarthritis. Kunobufakazi obuphikisanayo ngokusebenza kwe-glucosamine hydrochloride ye-osteoarthritis. Ubufakazi obuningi obusekela ukusetshenziswa kwe-glucosamine hydrochloride buvela ezifundweni zomkhiqizo othile (i-CosaminDS). Lo mkhiqizo uqukethe inhlanganisela ye-glucosamine hydrochloride, i-chondroitin sulfate, ne-manganese ascorbate. Obunye ubufakazi busikisela ukuthi le nhlanganisela ingathuthukisa ubuhlungu kubantu abane-osteoarthritis yamadolo. Le nhlanganisela ingasebenza kangcono kubantu abane-osteoarthritis emnene ukuya kokuphakathi kunabantu abane-osteoarthritis enamandla. Omunye umkhiqizo (Gurukosamin & Kondoroichin) oqukethe i-glucosamine hydrochloride, i-chondroitin sulfate, ne-quercetin glycosides nawo ubukeka uthuthukisa izimpawu zamadolo e-osteoarthritis.
  Imiphumela yokuthatha i-glucosamine hydrochloride kanye ne-chondroitin sulfate kuphela ixubekile. Obunye ubufakazi bukhombisa ukuthi ukuthatha umkhiqizo othize (iDroglican) oqukethe i-glucosamine hydrochloride ne-chondroitin sulfate kunciphisa izinhlungu kubantu abadala abane-osteoarthritis yamadolo. Kodwa-ke, olunye ucwaningo lubonisa ukuthi amafomula aqukethe i-glucosamine hydrochloride ne-chondroitin sulfate awasebenzi ekunciphiseni ubuhlungu ezigulini ezine-osteoarthritis yamadolo.
  Iningi locwaningo lukhombisa ukuthi ukuthatha i-glucosamine hydrochloride kuphela akubunciphisi ubuhlungu kubantu abane-osteoarthritis yamadolo.
  Ucwaningo oluningi lwenziwe kwi-glucosamine sulfate (bona uhlu oluhlukile) kune-glucosamine hydrochloride. Kunomcabango wokuthi i-glucosamine sulfate ingasebenza kangcono kune-glucosamine hydrochloride ye-osteoarthritis. Ucwaningo oluningi oluqhathanisa lezi zinhlobo ezimbili ze-glucosamine alukhombisanga mehluko. Kodwa-ke, abanye abacwaningi bagxeke ikhwalithi yezinye zalezi zifundo.
• Isifo samathambo (RA). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha umkhiqizo othile we-glucosamine hydrochloride (Rohto Pharmaceuticals Co.) kuhlanganiswe nemithi yokwelashwa kadokotela kunciphisa izinhlungu uma kuqhathaniswa nephilisi likashukela. Kodwa-ke, lo mkhiqizo awubonakali wehlisa ukuvuvukala noma wehlise inani lamalunga abuhlungu noma avuvukele.
• Unhlangothi. Abantu abathatha i-glucosamine bangaba nengozi ephansi kancane yokuba nesifo sohlangothi. Kepha akucaci ukuthi imuphi umthamo noma uhlobo lwe-glucosamine olungasebenza kahle kakhulu. Ezinye izinhlobo ze-glucosamine zifaka phakathi i-glucosamine sulfate ne-N-acetyl glucosamine. Akucaci futhi ukuthi le ngozi engezansi ivela ku-glucosamine noma ekulandeleni imikhuba yokuphila enempilo.
• Iqembu lezimo ezibuhlungu ezithinta ukuhlangana komhlathi nemisipha (izifo ze-temporomandibular noma i-TMD). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha inhlanganisela ye-glucosamine hydrochloride, i-chondroitin sulfate, ne-calcium ascorbate kabili ngosuku kunciphisa ukuvuvukala okuhlangene nobuhlungu, kanye nomsindo owenziwe ekuhlanganeni komhlathi, kubantu abanesifo se-temporomandibular.
• Iqembu lokuphazamiseka kwamehlo okungaholela ekulahlekelweni kombono (glaucoma).
• Ukuhlungu obusemhlane.
• Ukukhuluphala ngokweqile.
• Ezinye izimo.

Kudingeka ubufakazi obengeziwe ukukala i-glucosamine hydrochloride yalokhu kusetshenziswa.

I-Glucosamine emzimbeni isetshenziselwa ukwenza "isiguqo" esizungeze amalunga. Ku-osteoarthritis, lo mqhudelwano uba mncane futhi uqine. Ukuthatha i-glucosamine hydrochloride njengesengezo kungasiza ekunikezeni izinto ezidingekayo zokwakha kabusha isiguqo.

Abanye abacwaningi bakholelwa ukuthi i-glucosamine hydrochloride kungenzeka ingasebenzi kanye ne-glucosamine sulfate. Bacabanga ukuthi ingxenye ye- "sulphate" ye-glucosamine sulfate yinto ebalulekile ngoba i-sulfate iyadingeka emzimbeni ukukhiqiza uqwanga.

Lapho ithathwa ngomlomo: Glucosamine hydrochloride kuyinto OKUNGENZEKA UKUPHEPHA kubantu abadala abaningi lapho bethathwe ngomlomo ngokufanele kuze kube yiminyaka emi-2. I-Glucosamine hydrochloride ingadala igesi, ukuqunjelwa, kanye namajaqamba.

Eminye imikhiqizo ye-glucosamine ayiqukethe inani elifakwe ilebula le-glucosamine noma iqukethe inani eliningi ngokweqile le-manganese. Buza umhlinzeki wakho wezokunakekelwa kwezempilo mayelana nemikhiqizo ethembekile.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: Alukho ulwazi olwanele olwanele lokwazi ukuthi ngabe i-glucosamine hydrochloride iphephile yini ukuthi ingasetshenziswa lapho ukhulelwe noma uncelisa ibele. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Isifuba Somoya: I-Glucosamine hydrochloride ingenza i-asthma ibe yimbi kakhulu. Uma une-asthma, qaphela nge-glucosamine hydrochloride.

Isifo sikashukela: Olunye ucwaningo lokuqala lubonisa ukuthi i-glucosamine ingakhuphula ushukela wegazi kubantu abanesifo sikashukela. Kodwa-ke, ucwaningo olunokwethenjelwa kakhulu lukhombisa ukuthi i-glucosamine kubonakala ngathi ayikuthinti kakhulu ukulawula ushukela egazini kubantu abanesifo sikashukela sohlobo 2. I-Glucosamine enokuqapha ushukela wegazi ojwayelekile ibonakala iphephile kubantu abaningi abanesifo sikashukela.

I-Glaucoma: I-Glucosamine hydrochloride ingakhuphula ingcindezi ngaphakathi kweso futhi ingase ibe yimbi i-glaucoma. Uma une-glaucoma, khuluma nomhlinzeki wakho wezokunakekelwa kwempilo ngaphambi kokuthatha i-glucosamine.

I-cholesterol ephezulu: Kukhona ukukhathazeka okuthile ngokuthi i-glucosamine ingakhuphula amazinga e-cholesterol kwabanye abantu. I-Glucosamine ingakhuphula amazinga e-insulin. Amazinga aphezulu e-insulin ahlotshaniswa nokwanda kwamazinga e-cholesterol. Kodwa-ke, lo mphumela awuzange ubikwe kubantu. Ukuze ube ohlangothini oluphephile, gada amazinga akho e-cholesterol eduze uma uthatha i-glucosamine hydrochloride futhi unamazinga aphezulu e-cholesterol.

Umfutho wegazi ophezulu: Kunokukhathazeka okuthile ngokuthi i-glucosamine ingakhuphula umfutho wegazi kwabanye abantu. I-Glucosamine ingakhuphula amazinga e-insulin. Amazinga aphezulu e-insulin ahambisana nokukhuphuka kwengcindezi yegazi. Kodwa-ke, lo mphumela awuzange ubikwe kubantu. Ukuze ube sohlangothini oluphephile, hlola umfutho wegazi lakho eduze uma uthatha i-glucosamine hydrochloride futhi unengcindezi ephezulu yegazi.

Ukungezwani komzimba neshellfish: Kunokukhathazeka okuthile ukuthi imikhiqizo ye-glucosamine ingadala ukungezwani komzimba kubantu abazwela i-shellfish. I-Glucosamine ikhiqizwa kusuka kumagobolondo ezinhlanzi, ama-lobster kanye nonkala. Ukusabela okweqile kubantu abane-shellfish yokungezwani komzimba kubangelwa inyama ye-shellfish, hhayi igobolondo. Kepha abanye abantu bahlakulele ukusabela okweqile ngemuva kokusebenzisa izithako ze-glucosamine. Kungenzeka ukuthi eminye imikhiqizo ye-glucosamine ingahle ingcoliswe yingxenye yenyama ye-shellfish engadala ukusabela okweqile. Uma une-shellfish yokungezwani komzimba, khuluma nomhlinzeki wakho ngaphambi kokusebenzisa i-glucosamine.

Ukuhlinzwa: I-Glucosamine hydrochloride ingathinta amazinga kashukela egazini futhi ingaphazamisa ukulawulwa kukashukela egazini ngesikhathi nangemva kokuhlinzwa. Yeka ukusebenzisa i-glucosamine hydrochloride okungenani amasonto ama-2 ngaphambi kokuhlinzwa okuhleliwe.

Okukhulu

Ungathathi le nhlanganisela.

I-Warfarin (Coumadin)

I-Warfarin (i-Coumadin) isetshenziselwa ukunciphisa ukubamba kwegazi. Kunemibiko eminingana ekhombisa ukuthi ukuthatha i-glucosamine hydrochloride nge-chondroitin noma ngaphandle kwayo kukhulisa umphumela we-warfarin (Coumadin) ekunqandeni igazi. Lokhu kungadala ukulimala nokopha okungaba kubi kakhulu. Ungathathi i-glucosamine hydrochloride uma uthatha i-warfarin (Coumadin).

Maphakathi

Qaphela ngale nhlanganisela.

Imithi yomdlavuza (Topoisomerase II inhibitors)

Eminye imishanguzo yokusebenza komdlavuza ngokunciphisa ukuthi amangqamuzana omdlavuza ashesha kangakanani ukuzikopa. Abanye ososayensi bacabanga ukuthi i-glucosamine ingavimba le mithi ekunciphiseni ukuthi amangqamuzana ama-tumor ngokushesha angazikopisha kanjani. I-Glucosamine hydrochloride iyindlela eyodwa ye-glucosamine. Ukuthatha i-glucosamine hydrochloride kanye neminye imithi yomdlavuza kunganciphisa ukusebenza kwale mithi.

Eminye imithi esetshenziselwa umdlavuza ifaka i-etoposide (VP16, VePesid), teniposide (VM26), mitoxantrone, daunorubicin, ne-doxorubicin (Adriamycin).

Okuncane

Qaphela ngale nhlanganisela.

Imithi yesifo sikashukela (Imithi elwa nesifo sikashukela)

I-Glucosamine hydrochloride yindlela eyodwa ye-glucosamine. Kube nokukhathazeka ukuthi i-glucosamine ingakhuphula ushukela wegazi kubantu abanesifo sikashukela. Kubuye kwaba nokukhathazeka ukuthi i-glucosamine ingahle yehle ukuthi imishanguzo esetshenziselwa isifo sikashukela isebenza kahle kangakanani. Kodwa ucwaningo lwekhwalithi ephezulu manje lukhombisa ukuthi ukuthatha i-glucosamine hydrochloride mhlawumbe akukhuphuli ushukela wegazi noma kuphazamise imithi yesifo sikashukela kubantu abanesifo sikashukela. Kepha ukuze uqaphele, uma uthatha i-glucosamine hydrochloride futhi unesifo sikashukela, gada ushukela egazini lakho eduze.

Eminye imithi esetshenziselwa isifo sikashukela ifaka i-glimepiride (Amaryl), i-glyburide (i-DiaBeta, i-Glynase PresTab, i-Micronase), i-insulin, i-pioglitazone (i-Actos), i-rosiglitazone (i-Avandia), i-chlorpropamide (i-Diabinese), i-glipizide (i-Glucotrol), i-tolbutamide (i-Orinase), .

I-chondroitin sulfate

Ukuthatha i-chondroitin sulfate kanye ne-glucosamine hydrochloride kunganciphisa amazinga egazi e-glucosamine. Ngokwethiyori, ukuthatha i-glucosamine hydrochloride ne-chondroitin sulfate kunganciphisa ukumuncwa kwe-glucosamine hydrochloride.

Akukho ukuxhumana okwaziwayo nokudla.

Umthamo ofanele we-glucosamine hydrochloride uncike ezicini eziningana ezifana nobudala bomsebenzisi, impilo, nezinye izimo eziningana. Okwamanje alukho ulwazi olwanele lwesayensi lokunquma uhla olufanele lwamanani we-glucosamine hydrochloride. Khumbula ukuthi imikhiqizo yemvelo ayihlali iphephile njalo futhi imithamo ingabaluleka. Qiniseka ukuthi ulandela izinkomba ezifanele kumalebula womkhiqizo futhi uthintane nosokhemisi wakho noma udokotela noma omunye uchwepheshe wezokunakekelwa kwempilo ngaphambi kokusebenzisa.

(3R, 4R, 5S, 6R) -3-Amino-6- (Hydroxymethyl) i-Oxane-2,4,5-Triol Hydrochloride, 2-Amino-2-Deoxy-D-Glucosehydrochloride, 2-Amino-2-Deoxy- I-Beta-D-Glucopyranose, 2-Amino-2-Deoxy-Beta-D-Glucopyranose Hydrochloride, Amino Monosaccharide, Chitosamine Hydrochloride, Chlorhidrato de Glucosamina, Chlorhydrate de Glucosamine, D-Glucosamine HCl, Glucosamine Glucamine IGlucosamine KCl, iGlucosamine-6-Phosphate.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.

1. I-Kumar PNS, i-Sharma A, ne-Andrade C. Umshayeli wendiza, uphenyo olunelebula elisebenza ngokusebenza kweglucosamine ekwelapheni ukucindezeleka okukhulu. U-Asia J Psychiatr. 2020; 52: 102113. Buka okungaqondakali.
2. UMa H, uLi X, uZhou T, et al. Ukusetshenziswa kwe-Glucosamine, ukuvuvukala, kanye nokuthambekela kofuzo, kanye nesigameko sohlobo lwesifo sikashukela esingu-2: isifundo esizoba se-UK Biobank. Ukunakekelwa yisifo sikashukela. 2020; 43: 719-25. Buka okungaqondakali.
3. INavarro SL, Levy L, Curtis KR, Lampe JW, Hullar MAJ. Ukushintshashintsha kweGut Microbiota nguGlucosamine noChondroitin esivivinyweni esingahleliwe, esiphindwe kabili esimpumputhe esivivinyweni sabantu. Ama-microorganisms. 2019 Novemba 23; 7. pii: E610. Buka okungaqondakali.
4. URainaino OF, Finamore R, uStellavato A, et al. Izithako zokudla zase-European chondroitin sulfate kanye ne-glucosamine: Ukuhlolwa kwekhwalithi nokuhleleka okuhlelekile uma kuqhathaniswa nemithi yokwelapha. I-Carbohydr Polym. 2019 Okthoba 15; 222: 114984. Buka okungaqondakali.
5. UHoban C, uByard R, uMusgrave I. Ukusabela okweqile kwezidakamizwa ekulungiseni i-glucosamine kanye ne-chondroitin e-Australia phakathi kuka-2000 no-2011. I-Postgrad Med J. 2019 Oct 9. pii: postgradmedj-2019-136957. Buka okungaqondakali.
6. UKolasinski SL, uNeogi T, uHochberg MC, et al. Umhlahlandlela we-2019 American College of Rheumatology / Arthritis Foundation wokuphathwa kwe-osteoarthritis yesandla, inqulu, nedolo. I-Arthritis Rheumatol. 2020 uFebhu; 72: 220-33. Buka okungaqondakali.
7. UTsuruta A, uHoriike T, uYoshimura M, uNagaoka I. Ukuhlolwa komphumela wokuphathwa kwe-glucosamine equkethe isengezo kuma-biomarkers we-cartilage metabolism kubadlali bebhola: Isifundo esilawulwa ngokungahleliwe se-placebo blind blind. I-Mol Med Rep. 2018 Okthoba; 18: 3941-3948. I-Epub 2018 Aug 17. Buka okungaqondakali.
8. UMa H, Li X, uSun D, ​​et al. Inhlangano yokusetshenziswa okujwayelekile kwe-glucosamine ngengozi yesifo senhliziyo: okucatshangelwa ukuthi kufundwe e-UK Biobank. BMJ. 2019 Meyi 14; 365: l1628. Buka okungaqondakali.
9. I-Kanzaki N, i-Ono Y, i-Shibata H, i-Moritani T. Glucosamine equkethe isengezo ithuthukisa imisebenzi ye-locomotor ezifundweni ezinobuhlungu bamadolo: isifundo esilawulwa ngokungahleliwe, esimpumputhe, esilawulwa nge-placebo. Ukuguga Kwe-Clin Interv. 2015; 10: 1743-53. Buka okungaqondakali.
10. U-Esfandiari H, Pakravan M, Zakeri Z, et al. Umphumela we-glucosamine ekucindezelekeni kwe-intraocular: isilingo somtholampilo esingahleliwe. Iso. 2017; 31: 389-394.
11. UMurphy RK, uJaccoma EH, uRice RD, uKetzler L.Glucosamine njengesiKhathi Sengozi Esingaba khona seGlaucoma. Faka i-Ophthalmol Vis Sci 2009; 50: 5850.
12. U-Eriksen P, uBartels EM, u-Altman RD, uBliddal H, uJuhl C, uChristensen R. Ingozi yokwenzelela nomkhiqizo bachaza ukungahambelani okubonwayo ekuvivinyweni kwe-glucosamine ukuthola impumuzo ye-osteoarthritis: ukuhlaziywa kwe-meta kwezilingo ezilawulwa yi-placebo. I-Arthritis Care Res (iHoboken). 2014; 66: 1844-55. Buka okungaqondakali.
13. UMurphy RK, uKetzler L, uRice RD, uJohnson SM, uDoss MS, uJaccoma EH. Izithako zomlomo ze-glucosamine njenge-ocular hypertensive agent. UJAMA Ophthalmol 2013; 131: 955-7. Buka okungaqondakali.
14. ULevin RM, uKrieger NN, noWinzler RJ. I-Glucosamine nokubekezelelana kwe-acetylglucosamine kumuntu. UJ Lab Clin Med 1961; 58: 927-932.
15. UMeulyzer M, uVachon P, uBeaudry F, uVinardell T, uRichard H, uBeauchamp G, uLaverty S. Ukuqhathaniswa kwe-pharmacokinetics ye-glucosamine namazinga we-synovial fluid kulandela ukuphathwa kwe-glucosamine sulphate noma i-glucosamine hydrochloride. I-Osteoarthritis Cartilage 2008; 16: 973-9. Buka okungaqondakali.
16. U-Wu H, u-Liu M, u-Wang S, u-Zhao H, u-Yao W, u-Feng W, u-Yan M, u-Tang uY, u-Wei M. Ukuqhathanisa ukutholakala kokuzila ukudla kanye nezakhiwo ze-pharmacokinetic zokwenziwa kwe-2 kwe-glucosamine hydrochloride kumavolontiya amadala angamaShayina aphilile. Arzneimittelforschung. 2012 Aug; 62: 367-71. Buka okungaqondakali.
17. Liang CM, Tai MC, Chang YH, Chen YH, Chen CL, Chien MW, Chen JT. I-Glucosamine ivimbela ukwanda kwe-epidermal factor-induction nokwanda komjikelezo weseli kumaseli we-retinal pigment epithelial cell. I-Mol Vis 2010; 16: 2559-71. Buka okungaqondakali.
18. URaciti GA, Iadicicco C, Ulianich L, Vind BF, Gaster M, Andreozzi F, Longo M, Teperino R, Ungaro P, Di Jeso B, Formisano P, Beguinot F, Miele C.Ukucindezeleka kwe-endoplasmic reticulum okubangelwa yi-Glucosamine kuthinta ukukhuluma kwe-GLUT4 nge ukwenza into yokubhala engu-6 isebenze kumangqamuzana egundane namathambo omuntu. Isifo sikashukela 2010; 53: 955-65. Buka okungaqondakali.
19. Kang ES, Han D, Park J, Kwak TK, Oh MA, Lee SA, Choi S, Park ZY, Kim Y, Lee JW. Ukushintshashintsha kwe-O-GlcNAc e-Akt1 Ser473 kuhambisana ne-apoptosis yamaseli we-beta we-murine pancreatic. I-Exp Cell Res 2008; 314 (11-12): 2238-48. Buka okungaqondakali.
20. I-Yomogida S, i-Hua J, i-Sakamoto K, i-Nagaoka I. I-Glucosamine icindezela ukukhiqizwa kwe-interleukin-8 kanye nokuvezwa kwe-ICAM-1 ngamaseli e-TNF-alpha-evuselelwe ama-colonic epithelial HT-29 amaseli. I-Int J Mol Med 2008; 22: 205-11. Buka okungaqondakali.
21. UJu Y, Hua J, Sakamoto K, Ogawa H, Nagaoka I.Glucosamine, okwenzeka ngokwemvelo kwe-amino monosaccharide modulates LL-37-indased endothelial cell activation. I-Int J Mol Med 2008; 22: 657-62. Buka okungaqondakali.
22. I-Qiu W, i-Su Q, i-Rutledge AC, i-Zhang J, i-Adeli K. Glucosamine eyenziwe nge-endoplasmic reticulum stress inciphisa i-apolipoprotein B100 synthesis ngokusayina kwe-PERK. UJ Lipid Res 2009; 50: 1814-23. Buka okungaqondakali.
23. UJu Y, Hua J, Sakamoto K, Ogawa H, Nagaoka I. Ukushintshwa kwe-TNF-alpha-indosed endothelial cell activation yi-glucosamine, i-amino monosaccharide eyenzeka ngokwemvelo. I-Int J Mol Med 2008; 22: 809-15. Buka okungaqondakali.
24. U-Ilic MZ, uMartinac B, uSamiric T, uHandley CJ. Imiphumela ye-glucosamine ekulahlekelweni yi-proteoglycan nge-tendon, ligament kanye namasiko wokuhlola ama-capsule ahlangene. I-Osteoarthritis Cartilage 2008; 16: 1501-8. Buka okungaqondakali.
25. UToegel S, Wu SQ, Piana C, Unger FM, Wirth M, Goldring MB, Gabor F, Viernstein H. Ukuqhathanisa phakathi kwemiphumela ye-chondroprotective ye-glucosamine, i-curcumin, ne-diacerein kuma-chondrocyte e-IL-1beta akhuthazwe yi-C-28 / I2. I-Osteoarthritis Cartilage 2008; 16: 1205-12. Buka okungaqondakali.
26. I-Lin YC, i-Liang YC, i-Sheu MT, i-Lin YC, i-Hsieh MS, i-Chen TF, i-Chen CH. Imiphumela ye-Chondroprotective ye-glucosamine efaka i-p38 MAPK ne-Akt signaling pathways. IRheumatol Int 2008; 28: 1009-16. Buka okungaqondakali.
27. IScotto d'Abusco A, iPoliti L, iGiordano C, iScandurra R. Isisetshenziswa se-peptidyl-glucosamine sithinta umsebenzi we-IKKalpha kinase kuma-chondrocyte womuntu. I-Arthritis Res Ther 2010; 12: R18. Buka okungaqondakali.
28. UShikhman AR, uBrinson DC, uValbracht J, uLotz MK. Imiphumela ehlukile yemethabolic ye-glucosamine ne-N-acetylglucosamine kuma-chondrocyte womuntu wobuciko. I-Osteoarthritis Cartilage 2009; 17: 1022-8. Buka okungaqondakali.
29. Uitterlinden EJ, Koevoet JL, Verkoelen CF, Bierma-Zeinstra SM, Jahr H, Weinans H, Verhaar JA, van Osch GJ. I-Glucosamine yandisa ukukhiqizwa kwe-hyaluronic acid kuma-osteoarthritic synovium explants. I-BMC Musculoskelet Disord 2008; 9: 120. Buka okungaqondakali.
30. Hong H, Park YK, Choi MS, Ryu NH, Ingoma DK, Suh SI, Nam KY, Park GY, Jang BC. Ukwehluka kokulawulwa phansi kwe-COX-2 ne-MMP-13 kuma-fibroblast esikhumba somuntu yi-glucosamine-hydrochloride. J I-Dermatol Sci 2009; 56: 43-50. Buka okungaqondakali.
31. I-Wu YL, Kou YR, Ou HL, Chien HY, Chuang KH, Liu HH, Lee TS, Tsai CY, Lu ML. Ukulawulwa kwe-Glucosamine kokuvuvukala okuphakathi kwe-LPS kumaseli womuntu we-bronchial epithelial. I-Eur J Pharmacol 2010; I-635 (1-3): 219-26. Buka okungaqondakali.
32. Imagawa K, de Andrés MC, Hashimoto K, Pitt D, Itoi E, Goldring MB, Roach HI, Oreffo RO. Umphumela we-epigenetic we-glucosamine kanye ne-nuclear factor-kappa B (NF-kB) inhibitor kuma-chondrocyte ayisisekelo abantu - imiphumela ye-osteoarthritis. I-Biochem Biophys Res Commun 2011; 405: 362-7. Buka okungaqondakali.
33. I-Yomogida S, i-Kojima Y, i-Tsutsumi-Ishii Y, i-Hua J, i-Sakamoto K, i-Nagaoka I. I-Glucosamine, i-amino monosaccharide eyenzeka ngokwemvelo, icindezela i-dextran sulfate colitis eyenziwe nge-sodium kumagundane. I-Int J Mol Med 2008; 22: 317-23. Buka okungaqondakali.
34. I-Sakai S, i-Sugawara T, i-Kishi T, i-Yanagimoto K, i-Hirata T. Umphumela we-glucosamine kanye nezinhlanganisela ezihlobene nokwehliswa kwamangqamuzana omzimba nokuvuvukala kwezindlebe okubangelwa yi-dinitrofluorobenzene kumagundane. Impilo Sci 2010; 86 (9-10): 337-43. Buka okungaqondakali.
35. IHwang MS, iBaek WK. I-Glucosamine inciphisa ukufa kweseli okuzenzakalelayo ngokukhuthaza ukucindezeleka kwe-ER kumaseli womdlavuza womuntu we-glioma. I-Biochem Biophys Res Commun 2010; 399: 111-6. Buka okungaqondakali.
36. IPark JY, iPark JW, iSuh SI, iBaek WK. I-D-glucosamine phansi-ilawula i-HIF-1alpha ngokuvimbela ukuhumusha kwamaprotheni kumaseli womdlavuza we-DU145. I-Biochem Biophys Res Commun 2009; 382: 96-101. Buka okungaqondakali.
37. I-Chesnokov V, i-Sun C, i-Itakura K. I-Glucosamine icindezela ukwanda kwamangqamuzana e-prostate carcinoma DU145 ngokuvimbela ukusayinwa kwe-STAT3. ICancer Cell Int 2009; 9:25. Buka okungaqondakali.
38. Tsai CY, Lee TS, Kou YR, Wu YL. I-Glucosamine ivimbela ukukhiqizwa kwe-IL-1beta-mediated IL-8 kumaseli womdlavuza wesibeletho ngokunqanyulwa kwe-MAPK. I-J Cell Biochem 2009; 108: 489-98. Buka okungaqondakali.
39. UKim DS, iPark KS, uJeong KC, uLee BI, uLee CH, uKim SY. I-Glucosamine iyi-chemo-sensitizer esebenzayo nge-transglutaminase 2 inhibition. I-Cancer Lett 2009; 273: 243-9. Buka okungaqondakali.
40. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T. O-glycosylation weFoxO1 kwandisa umsebenzi wayo wokubhala ubheke kuhlobo lwe-glucose 6-phosphatase. FEBS Lett 2008; 582: 829-34. Buka okungaqondakali.
41. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T. O-GlcNAc ukuguqulwa kweFoxO1 kwandisa umsebenzi wayo wokubhala: indima endabeni yeglucotoxicity? I-Biochimie 2008; 90: 679-85. Buka okungaqondakali.
42. UNaito K, Watari T, Furuhata A, Yomogida S, Sakamoto K, Kurosawa H, Kaneko K, Nagaoka I. Ukuhlolwa komphumela we-glucosamine kwimodeli yokuhlola yama-rat osteoarthritis. Impilo Sci 2010; 86 (13-14): 538-43. Buka okungaqondakali.
43. I-Weiden S ne-Wood IJ. Isiphetho se-glucosamine hydrochloride sijojowe ngomjovo kumuntu. UJ Clin Pathol 1958; 11: 343-349.
44. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. I-Cancer Epidemiol Biomarkers Prev 2009; 18: 1419-28. Buka okungaqondakali.
45. I-Audimoolam VK, Bhandari S. Acute interstitial nephritis ebangelwa yi-glucosamine. Ukufakelwa kweNephrol Dial 2006; 21: 2031. Buka okungaqondakali.
46. Ossendza RA, Grandval P, Chinoune F, Rocher F, Chapel F, Bernardini D. [Acute cholestatic hepatitis ngenxa yeglucosamine forte]. IGastroenterol Clin Biol. 2007 Ephreli; 31: 449-50. Buka okungaqondakali.
47. UWu D, uHuang Y, uGu Y, uFan W. Ukusebenza kwamalungiselelo ehlukene we-glucosamine ekwelapheni i-osteoarthritis: ukuhlaziywa kwe-meta kokuhlolwa okulawulwa ngokungahleliwe, okuyimpumputhe, nokulawulwa kwe-placebo. I-Int J Clin Pract 2013; 67: 585-94. Buka okungaqondakali.
48. I-Provenza JR, iShinjo SK, iSilva JM, iPeron CR, iRocha FA. I-glucosamine ehlanganisiwe ne-chondroitin sulfate, kanye noma kathathu nsuku zonke, ihlinzeka nge-analgesia efanelekile emtholampilo ku-knee osteoarthritis. I-Clin Rheumatol 2015; 34: 1455-62. Bheka okungaqondakali.
49. I-Kwoh CK, i-Roemer FW, i-Hannon MJ, i-Moore CE, i-Jakicic JM, i-Guermazi A, i-Green SM, i-Evans RW, i-Boudreau R. Umphumela we-glucosamine yomlomo ekwakhiweni okuhlangene kubantu abanezinhlungu ezingapheli zamadolo: isilingo somtholampilo esilawulwa ngokungahleliwe. I-Arthritis Rheumatol. 2014 Ephreli; 66: 930-9. Buka okungaqondakali.
50. UHochberg MC, uMartel-Pelletier J, uMonfort J, uMöller I, uCastillo JR, u-Arden N, uBerenbaum F, uBlanco FJ, uConaghan PG, uDoménech G, uHenrotin Y, uPap T, uRichette P, uSawitzke A, uDu Souich P, uPelletier JP ; egameni le-MOVES Investigation Group. I-chondroitin sulphate ne-glucosamine ehlanganisiwe ye-osteoarthritis yamadolo ebuhlungu: isilingo se-multicentre, randomized, blind-blind, non-inferiority versus celecoxib. U-Ann Rheum Dis 2016; 75: 37-44. Buka okungaqondakali.
51. UCerda C, Bruguera M, Parés A. Hepatotoxicity ehambisana ne-glucosamine ne-chondroitin sulfate ezigulini ezinesifo esingalapheki sesibindi. Umhlaba J Gastroenterol 2013; 19: 5381-4. Buka okungaqondakali.
52. I-Glucosamine yamadolo i-osteoarthritis - yini okusha? Izidakamizwa Ther Bull. 2008: 46: 81-4. Buka okungaqondakali.
53. UFox BA, uStephens MM. I-Glucosamine hydrochloride yokwelashwa kwezimpawu ze-osteoarthritis. Ukuguga Kwe-Clin Interv 2007; 2: 599-604. Buka okungaqondakali.
54. IVeldhorst, MA, Nieuwenhuizen, AG, Hochstenbach-Waelen, A., van Vught, AJ, Westerterp, KR, Engelen, MP, Brummer, RJ, Deutz, NE, noWesterterp-Plantenga, umphumela wokunciphiswa okuncike ku-MS Dose we-whey isihlobo i-casein noma i-soy. UPhysiol Behav 3-23-2009; 96 (4-5): 675-682. Buka okungaqondakali.
55. UYue, J., Yang, M., Yi, S., Dong, B., Li, W., Yang, Z., Lu, J., Zhang, R., no-Yong, J. Chondroitin sulfate kanye / noma i-glucosamine hydrochloride yesifo sikaKashin-Beck: isifundo esilawulwa yiqoqo elilawulwa ngokungahleliwe. I-Osteoarthritis.Cartilage. 2012; 20: 622-629. Buka okungaqondakali.
56. UKanzaki, N., Saito, K., Maeda, A., Kitagawa, Y., Kiso, Y., Watanabe, K., Tomonaga, A., Nagaoka, I., noJamaguchi, H. Umphumela wesengezo sokudla. equkethe i-glucosamine hydrochloride, i-chondroitin sulphate ne-quercetin glycosides ku-osteoarthritis enophawu: isifundo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. J.Sci.Izolimo Zokudla. 3-15-2012; 92: 862-869. Buka okungaqondakali.
57. USawitzke, AD, Shi, H., Finco, MF, Dunlop, DD, Harris, CL, Singer, NG, Bradley, JD, Silver, D., Jackson, CG, Lane, NE, Oddis, CV, Wolfe, F. , Lisse, J., Furst, DE, Bingham, CO, Reda, DJ, Moskowitz, RW, Williams, HJ, noClegg, DO Clinical efficacy and safety of glucosamine, chondroitin sulphate, inhlanganisela yabo, i-celecoxib noma i-placebo ethathwe ukwelapha i-osteoarthritis wamadolo: imiphumela yeminyaka emi-2 evela ku-GAIT. UMnu. Ann. 2010; 69: 1459-1464. Buka okungaqondakali.
58. UJackson, CG, Plaas, AH, Sandy, JD, Hua, C., Kim-Rolands, S., Barnhill, JG, Harris, CL, noClegg, DO Ama-pharmacokinetics womuntu wokufaka ngomlomo i-glucosamine ne-chondroitin sulfate ethathwe ngokwahlukana noma ngokuhlangana. I-Osteoarthritis Cartilage 2010; 18: 297-302. Buka okungaqondakali.
59. I-Dudics, V., Kunstar, A., Kovacs, J., Lakatos, T., Geher, P., Gomor, B., Monostori, E., no-Uher, F. Amandla weChondrogenic wamaseli we-mesenchymal stem avela ezigulini ezine-rheumatoid. i-arthritis ne-osteoarthritis: izilinganiso ohlelweni lwe-microculture. Amaseli izicubu.Izinhlelo 2009; 189: 307-316. Buka okungaqondakali.
60. INandhakumar J. Ukusebenza, ukubekezelelana, nokuphepha kwe-anti-inflammatory enezinto eziningi ezine-glucosamine hydrochloride vs glucosamine sulfate vs i-NSAID ekwelapheni i-knee osteoarthritis - isifundo esingahleliwe, esizoba khona, esimpumputhe kabili. I-Integr Med Clin J 2009; 8: 32-38.
61. UKawasaki T, Kurosawa H, Ikeda H, et al. Imiphumela eyengeziwe ye-glucosamine noma i-risedronate ekwelapheni i-osteoarthritis yamadolo kuhlangene nokuzivocavoca kwasekhaya: isilingo esingahle senziwe ngokungahleliwe sezinyanga eziyi-18. UJ Bone Miner Metab 2008; 26: 279-87. Buka okungaqondakali.
62. UNelson BA, uRobinson KA, uBuse MG. I-glucose ephezulu ne-glucosamine yenza ukumelana ne-insulin ngezinqubo ezahlukahlukene kuma-adipocyte e-3T3-L1. Isifo sikashukela 2000; 49: 981-91. Buka okungaqondakali.
63. UBaron AD, uZhu JS, uZhu JH, et al. I-Glucosamine inciphisa ukumelana ne-insulin ku-vivo ngokuthinta ukuhanjiswa kwe-GLUT 4 emisipheni yamathambo. Imiphumela yeshukela le-glucose. UJ Clin Invest 1995; 96: 2792-801. Buka okungaqondakali.
64. U-Eggertsen R, Andreasson A, Andren L. Azikho izinguquko zamazinga e-cholesterol ngomkhiqizo we-glucosamine otholakala ngokuthengisa ezigulini ezelashwa ngemithi yokwehlisa i-lipid: isivivinyo esilawulwayo, esingahleliwe, esivulekile. I-BMCPharmacol Toxicol 2012; 13: 10. Buka okungaqondakali.
65. I-Shankland WE. Imiphumela ye-glucosamine ne-chondroitin sulfate ku-osteoarthritis ye-TMJ: umbiko wokuqala weziguli ezingama-50. Cranio 1998; 16: 230-5. Buka okungaqondakali.
66. U-Liu W, uLiu G, uPei F, et al. Isifo seKashin-Beck eSichuan, eChina: umbiko wesilingo esivula isilingo sokwelapha. UJ Clin Rheumatol 2012; 18: 8-14. Buka okungaqondakali.
67. U-Lee JJ, uJin YR, u-Lee JH, et al. Umsebenzi we-antiplatelet we-carnosic acid, i-phenolic diterpene evela ku-Rosmarinus officinalis. UPlanta Med 2007; 73: 121-7. Buka okungaqondakali.
68. UNakamura H, Masuko K, Yudoh K, et al. Imiphumela yokuphathwa kwe-glucosamine ezigulini ezinesifo samathambo. IRheumatol Int 2007; 27: 213-8. Buka okungaqondakali.
69. I-Yue QY, iStrandell J, iMyrberg O. Ukusetshenziswa okuhambisanayo kwe-glucosamine kungahle kube nomphumela we-warfarin. Isikhungo Sokuqapha i-Uppsala. Kutholakala ku: www.who-umc.org/graphics/9722.pdf (Kufinyelelwe ngomhla ka-28 Ephreli 2008).
70. UKnudsen J, uSokol GH. Ukusebenzisana okungenzeka kwe-glucosamine-warfarin okuholele ekukhuleni kwesilinganiso esijwayelekile somhlaba jikelele: Umbiko wecala nokubuyekezwa kwemibhalo kanye nedatha ye-MedWatch. I-Pharmacotherapy 2008; 28: 540-8. Buka okungaqondakali.
71. UMuniyappa R, Karne RJ, Hall G, et al. I-Oral glucosamine yamaviki ayisithupha ngamanani avamile ayibangeli noma yenze kube nzima ukumelana ne-insulin noma ukungasebenzi kahle kwe-endothelial ezifundweni ezincikile noma ezikhuluphele. Isifo sikashukela 2006; 55: 3142-50. Buka okungaqondakali.
72. UTannock LR, Kirk EA, King VL, et al. Isengezo se-Glucosamine sisheshisa i-atherosclerosis yokuqala kodwa hhayi sekwephuzile kumagundane angenele we-LDL. J Izakhi 2006; 136: 2856-61. Buka okungaqondakali.
73. UPham T, uCornea A, uBlick KE, et al. I-Oral glucosamine ngemithamo esetshenziselwa ukwelapha i-osteoarthritis yandisa ukumelana ne-insulin. Ngingu-J Med Sci 2007; 333: 333-9. Buka okungaqondakali.
74. UMessier SP, uMihalko S, uLoeser RF, et al. I-Glucosamine / chondroitin ehlanganiswe nokuvivinya umzimba ekwelapheni i-knee osteoarthritis: isifundo sokuqala. I-Osteoarthritis Cartilage 2007; 15: 1256-66. Buka okungaqondakali.
75. IStumpf JL, iLin SW. Umphumela we-glucosamine ekulawuleni i-glucose. U-Ann Pharmacother 2006; 40: 694-8. Buka okungaqondakali.
76. I-Qiu GX, i-Weng XS, uZhang K, et al. [Isivivinyo somtholampilo esimaphakathi nendawo, esingahleliwe, esilawulwayo se-glucosamine hydrochloride / sulfate ekwelapheni i-knee osteoarthritis]. UZhonghua Yi Xue Za Zhi 2005; 85: 3067-70. Buka okungaqondakali.
77. UClegg DO, uReda DJ, uHarris CL, et al. I-Glucosamine, i-chondroitin sulfate, kanye nalokhu okubili kuhlangene i-osteoarthritis yamadolo ebuhlungu. N Engl J Med 2006; 354: 795-808. Buka okungaqondakali.
78. UMcAlindon T. Kungani izilingo zomtholampilo ze-glucosamine zingasasebenzi ngokufanayo? Rheum Dis Clin North Am 2003; 29: 789-801. Buka okungaqondakali.
79. UTannis AJ, uBarban J, uConquer JA. Umphumela we-glucosamine supplementation ekuzileni nasekungazameni ukudla kwe-plasma glucose kanye nokugxila kwe-serum insulin kubantu abaphilile. I-Osteoarthritis Cartilage 2004; 12: 506-11. Buka okungaqondakali.
80. UWeimann G, uLubenow N, uSelleng K, et al. I-Glucosamine sulfate ayihambelani nama-antibodies eziguli ezine-heparin-induced thrombocytopenia. I-Eur J Haematol 2001; 66: 195-9. Buka okungaqondakali.
81. URozenfeld V, uCrain JL, uCallahan AK. Ukwanda okungenzeka komphumela we-warfarin yi-glucosamine-chondroitin. NginguJ J Health Syst Pharm 2004; 61: 306-307. Buka okungaqondakali.
82. Ilungu lePhalamende laseGuillaume, uPeretz A.Ukuhlangana okungenzeka phakathi kokwelapha i-glucosamine nobuthi bezinso: phawula encwadini ebhalwe nguDanao-Camara. I-Arthritis Rheum 2001; 44: 2943-4. Buka okungaqondakali.
83. UDanao-Camara T. Imiphumela engemihle yokwelashwa nge-glucosamine ne-chondroitin. I-Arthritis Rheum 2000; 43: 2853. Buka okungaqondakali.
84. U-Yu JG, uBoies SM, u-Olefsky JM. Umphumela we-oral glucosamine sulfate ekuzweleni kwe-insulin ezifundweni zabantu. Ukunakekelwa yisifo sikashukela 2003; 26: 1941-2. Buka okungaqondakali.
85. UHoffer LJ, uKaplan LN, uHamadeh MJ, et al. I-Sulphate ingalamula umphumela wokwelapha we-glucosamine sulfate. I-Metabolism 2001; 50: 767-70 .. Buka okungaqondakali.
86. Braham R, Dawson B, Goodman C. Umphumela we-glucosamine supplementation kubantu ababhekene nobuhlungu bamadolo obujwayelekile. UBr J Sports Med 2003; 37: 45-9. Buka okungaqondakali.
87. UScroggie DA, Albright A, uHarris MD. Umphumela we-glucosamine-chondroitin supplementation kumazinga we-hemoglobin we-glycosylated ezigulini ezinesifo sikashukela sohlobo 2: isilingo somtholampilo esilawulwa yi-placebo, esimpumputhe kabili, esingahleliwe. I-Arch Intern Med 2003; 163: 1587-90. Buka okungaqondakali.
88. UTallia AF, uCardone DA. Ukukhuphuka kwesifuba somoya okuhambisana nesengezo se-glucosamine-chondroitin. J Am Board Fam Pract 2002; 15: 481-4 .. Buka okungaqondakali.
89. UDu XL, u-Edelstein D, uDimmeler S, et al. I-Hyperglycemia ivimbela umsebenzi we-endothelial nitric oxide synthase ngokuguqulwa kokuhumusha ngemuva kusiza se-Akt. UJ Clin Invest 2001; 108: 1341-8. Buka okungaqondakali.
90. UPavelka K, uGatterova J, u-Olejarova M, et al. Ukusetshenziswa kwe-Glucosamine sulfate nokubambezeleka kokuqhubekela phambili kwe-osteoarthritis yamadolo: Ucwaningo lweminyaka emithathu, olulawulwa ngokungahleliwe, olulawulwa yi-placebo, oluyimpumputhe kabili. I-Arch Intern Med 2002; 162: 2113-23. Buka okungaqondakali.
91. I-Adebowale AO, iCox DS, uLiang Z, et al. Ukuhlaziywa kokuqukethwe kwe-glucosamine ne-chondroitin sulphate kumikhiqizo emakethwayo kanye nokutholakala kwe-Caco-2 kwezinto zokusetshenziswa ze-chondroitin sulfate. UJANA 2000; 3: 37-44.
92. UNowak A, uSzczesniak L, uRychlewski T, et al. Amazinga e-Glucosamine kubantu abanesifo senhliziyo esineschemic abanesifo sikashukela sohlobo II nangaphandle kwaso. IPol Arch Med Wewn 1998; 100: 419-25. Buka okungaqondakali.
93. U-Olszewski AJ, uSzostak WB, uMcCully KS. I-Plasma glucosamine ne-galactosamine kusifo senhliziyo esibuhlungu. I-Atherosclerosis 1990; 82: 75-83. Buka okungaqondakali.
94. U-Yun J, uTomida A, uNagata K, uTsuruo T. Ukucindezelwa okulawulwa yi-Glucose kunikeza ukumelana ne-VP-16 kumaseli womdlavuza womuntu ngokuncipha kokwehla kwe-DNA topoisomerase II. I-Oncol Res 1995; 7: 583-90. Buka okungaqondakali.
95. UPouwels MJ, uJacobs JR, uSpan PN, et al. Ukumnika okwesikhashana esifushane i-glucosamine akuthinti ukuzwela kwe-insulin kubantu. UJ Clin Endocrinol Metab 2001; 86: 2099-103. Buka okungaqondakali.
96. UMonauni T, uZenti MG, uCretti A, et al. Imiphumela ye-glucosamine infusion ekusithekeni kwe-insulin kanye nesenzo se-insulin kubantu. Isifo sikashukela 2000; 49: 926-35. Buka okungaqondakali.
97. UDas A Jr, uHammad TA. Ukusebenza kwenhlanganisela ye-FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. I-Osteoarthritis Cartilage 2000; 8: 343-50. Buka okungaqondakali.
98. IBhodi Yezokudla Nezokudla, Isikhungo Sezokwelapha. Ukufakwa Kwezikhombo Zezokudla ku-Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, neZinc. Washington, DC: National Academy Press, 2002. Itholakala ku: www.nap.edu/books/0309072794/html/.
99. Ngabe i-glucosamine inyusa amazinga e-serum lipid nomfutho wegazi? Incwadi ka-Pharmacist's Letter / Prescriber's 2001; 17: 171115.
100. UReginster JY, uDeroisy R, uRovati LC, et al. Imiphumela yesikhathi eside ye-glucosamine sulfate ekuqhubekeni kwe-osteoarthritis: isilingo esilawulwa ngokungahleliwe, esilawulwa yi-placebo. ILancet 2001; 357: 251-6. Buka okungaqondakali.
101. I-Almada A, i-Harvey P, i-Platt K. Imiphumela ye-oral glucosamine sulphate ekuzileni i-insulin insulin index index (FIRI) kubantu abangasifo sikashukela. I-FASEB J 2000; 14: A750.
102. Leffler CT, Philippi AF, Leffler SG, et al. I-Glucosamine, i-chondroitin, ne-manganese ascorbate yesifo esihlanganayo esiwohlokayo emadolweni noma emuva okuphansi: isifundo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. IMil Med 1999; 164: 85-91. Buka okungaqondakali.
103. UShankar RR, uZhu JS, uBaron AD. Ukufakwa kwe-Glucosamine kumagundane kulingisa ukungasebenzi kahle kwe-beta-cell yesifo sikashukela esingancikile ku-insulin. IMetabolism 1998; 47: 573-7. Buka okungaqondakali.
104. URossetti L, uHawkins M, Chen W, et al. Ku-vivo glucosamine ukumnika kukhuthaza ukumelana ne-insulin kuma-normoglycemic kepha hhayi kumagundane we-hyperglycemic. UJ Clin Invest 1995; 96: 132-40. Buka okungaqondakali.
105. IHupt JB, McMillan R, Wein C, Paget-Dellio SD. Umphumela we-glucosamine hydrochloride ekwelapheni ubuhlungu be-osteoarthritis yamadolo. UJ Rheumatol 1999; 26: 2423-30. Buka okungaqondakali.
106. UKim YB, uZhu JS, uZierath JR, et al. Ukufakwa kwe-Glucosamine kumagundane kuphazamisa ngokushesha ukuvuselelwa kwe-insulin ye-phosphoinositide 3-kinase kepha akuguquli ukwenziwa kwe-Akt / protein kinase B emisipha yamathambo. Isifo sikashukela 1999; 48: 310-20. Buka okungaqondakali.
107. UHolmang A, uNilsson C, uNiklasson M, et al. Ukwenziwa kwe-insulin ukumelana yi-glucosamine kunciphisa ukugeleza kwegazi kepha hhayi amazinga we-glucose noma i-insulin. Isifo sikashukela 1999; 48: 106-11. Buka okungaqondakali.
108. UGiaccari A, uMorviducci L, uZorretta D, et al. Emiphumeleni ye-vivo ye-glucosamine ekusithekeni kwe-insulin nokuzwela kwe-insulin kumagundane: ukuhambisana okungenzeka nezimpendulo ezingalungile ku-hyperglycaemia engapheli. Isifo sikashukela 1995; 38: 518-24. Buka okungaqondakali.
109. I-Balkan B, i-Dunning BE. I-Glucosamine inqanda i-glucokinase in vitro futhi ikhiqize ukukhubazeka okuqondene noshukela we-vivo insulin secretion kumagundane. Isifo sikashukela 1994; 43: 1173-9. Buka okungaqondakali.
110. U-Adams ME. Thayipha nge-glucosamine. ILancet 1999; 354: 353-4. Buka okungaqondakali.
111. UGruenwald J, Brendler T, Jaenicke C. PDR weMithi Yemithi. 1st ed. IMontvale, NJ: I-Medical Economics Company, Inc., ngo-1998.
112. USchulz V, uHansel R, uTyler VE. I-Rational Phytotherapy: Umhlahlandlela Wodokotela Emithini Yezokwelapha. Terry C. Telger, ukuhumusha 3rd ed. IBerlin, iGER: Springer, 1998.
113. UBlumenthal M, u-ed. I-Complete German Commission E Monographs: Umhlahlandlela Wezokwelapha Emithini Yemithi. I-Trans. S. Klein. IBoston, MA: Umkhandlu Wezamabhodlela waseMelika, ngo-1998.
114. Ama-monographs ngokusetshenziswa kokwelashwa kwemithi yezitshalo. I-Exeter, e-UK: I-European Scientific Co-op Phytother, ngo-1997.

Kugcine ukubuyekezwa - 10/23/2020